Reversal of a Neurologic Paraneoplastic Syndrome with Octreotide (Sandostatin) in a Pt with Glucagonoma
Am J Med 91:434-436, Holmes,A.,et al, 1991
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
Acromegaly
NEJM 322:966-977, Melmed,S., 1990
Treatment of Autonomic Neuropathy with a Somatostatin Analogue SMS-201-995
Lancet 2:602-605, Hoeldtke,R.D.,et al, 1986
Reversible Parkinsonism and Ataxia Associated With High-Dose Octreotide
Neurol 70:2345-2346, Espay,A.J., 2008
Management of Pituitary Tumors
Ann Int Med 129:472-483, Shimon,I.&Melmed,S., 1998
Octreotide
NEJM 334:246-254, Lamberts,S.W.J.,et al, 1996
Consensus Statement:Benefits VS Risk of Medical Therapy for Acromegaly
Am J Med 97:468-473, Melmed,S.,et al, 1994
Acromegaly:Treatment After 100 Years
BMJ 307:1505-1506, Wass,J.A.H., 1993
Octreotide Treatment of Acromegaly, A Randomized, Multicenter Study
Ann Int Med 117:711-718, Ezzat,S.,et al, 1992
Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991
Long-term Treatment of 189 Acromegalic Patients with the Somatostatin Analog Octreotide
Arch Int Med 151:1573-1578, Vance,M.L.&Harris,A.G., 1991
Therapeutic Efficacy of the Somatostatin Analog SMS 201-995 (Octreotide) in Acromegaly
Ann Int Med 112:173-181, Ho,K.Y.,et al, 1990
Treatment of Acromegaly with a Somatostatin Analog in a Patient with McCune-Albright Syndrome
J Pediatr 111:740-743, Geffner,M.E.,et al, 1987